See more : STORE Capital Corporation (STOR) Income Statement Analysis – Financial Results
Complete financial analysis of Dyadic International, Inc. (DYAI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dyadic International, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- American Education Center, Inc. (AMCT) Income Statement Analysis – Financial Results
- Honeys Holdings Co., Ltd. (2792.T) Income Statement Analysis – Financial Results
- Hitachi Construction Machinery Co., Ltd. (6305.T) Income Statement Analysis – Financial Results
- Major Cineplex Group Public Company Limited (MAJOR-R.BK) Income Statement Analysis – Financial Results
- Newtech Co.,Ltd. (6734.T) Income Statement Analysis – Financial Results
Dyadic International, Inc. (DYAI)
About Dyadic International, Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.90M | 2.93M | 2.40M | 1.60M | 1.68M | 1.30M | 758.42K | 592.89K | 315.71K | 12.52M | 17.13M | 15.60M | 15.38M | 15.88M | 16.74M | 211.27K |
| Cost of Revenue | 1.98M | 2.12M | 1.94M | 1.42M | 1.46M | 1.03M | 680.20K | 516.16K | 124.01K | 8.18M | 9.72M | 7.62M | 11.35M | 12.86M | 12.83M | 175.44K |
| Gross Profit | 922.96K | 807.11K | 459.39K | 176.99K | 221.38K | 268.17K | 78.22K | 76.72K | 191.70K | 4.35M | 7.41M | 7.99M | 4.04M | 3.03M | 3.91M | 35.83K |
| Gross Profit Ratio | 31.84% | 27.54% | 19.11% | 11.05% | 13.17% | 20.70% | 10.31% | 12.94% | 60.72% | 34.71% | 43.25% | 51.18% | 26.25% | 19.05% | 23.34% | 16.96% |
| Research & Development | 3.30M | 4.50M | 8.39M | 3.87M | 3.96M | 3.32M | 2.20M | 885.60K | 124.01K | 2.19M | 1.00M | 921.71K | 4.24M | 4.90M | 3.62M | 0.00 |
| General & Administrative | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 6.11M | 4.99M | 4.48M | 7.15B | 5.32M | 3.76M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 944.12K | 700.78K | 3.42B | 2.81M | 1.86M | 0.00 |
| SG&A | 5.82M | 6.42M | 6.70M | 6.08M | 5.52M | 4.52M | 5.03M | 4.56M | 3.84M | 7.36M | 5.94M | 5.50M | 10.57M | 8.13M | 5.61M | 42.54K |
| Other Expenses | 38.42K | 250.00K | 6.09M | 187.39K | 2.30M | 2.04M | 220.72K | 436.92K | 0.00 | 0.00 | 0.00 | 0.00 | -28.70K | -16.79K | 0.00 | 184.07K |
| Operating Expenses | 9.15M | 10.92M | 15.09M | 10.14M | 9.48M | 7.84M | 7.45M | 5.88M | 3.84M | 9.55M | 6.94M | 5.87M | 14.77M | 13.01M | 9.24M | 226.61K |
| Cost & Expenses | 11.13M | 13.05M | 17.03M | 11.57M | 10.94M | 8.87M | 8.13M | 6.40M | 3.96M | 17.72M | 16.66M | 13.49M | 26.12M | 25.87M | 22.07M | 402.05K |
| Interest Income | 416.69K | 180.42K | 51.70K | 447.00K | 984.93K | 0.00 | 0.00 | 485.49K | 11.16K | 28.06K | 14.61K | 695.85K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 894.53K | 566.15K | 909.00 | 11.16K | 683.21K | 686.02K | 0.00 | 594.16K | 710.54K | 597.91K | 0.00 |
| Depreciation & Amortization | 0.00 | 10.12M | 3.49M | 9.96M | 9.25M | 7.40M | 7.38M | 5.81M | -2.17M | 271.13K | 253.50K | 256.48K | 250.18K | 602.73K | 586.69K | 0.00 |
| EBITDA | -8.23M | -10.07M | -13.07M | -10.19M | -9.23M | -7.55M | -2.20M | 0.00 | -5.82M | -5.45M | 726.69K | 1.82M | -9.91M | -9.13M | -4.87M | -190.78K |
| EBITDA Ratio | -283.90% | -343.51% | -671.40% | -635.84% | -548.88% | -582.88% | -1,580.02% | -897.71% | -1,842.27% | -39.11% | 4.33% | 11.65% | -71.47% | -60.63% | -27.04% | -90.30% |
| Operating Income | -8.23M | -10.12M | -14.73M | -10.03M | -9.28M | -7.59M | -7.13M | -5.96M | -3.65M | -5.32M | 556.50K | 1.56M | -10.74M | -9.99M | -5.33M | -190.78K |
| Operating Income Ratio | -283.90% | -345.21% | -612.67% | -625.85% | -552.18% | -586.09% | -939.70% | -1,004.45% | -1,154.93% | -42.52% | 3.25% | 10.00% | -69.78% | -62.87% | -31.82% | -90.30% |
| Total Other Income/Expenses | 1.43M | 430.42K | 1.66M | 731.71K | 984.93K | 894.53K | 4.92M | 2.58M | 2.18M | 47.81K | -984.55K | -142.86K | -41.87K | -442.94K | -725.71K | 190.78K |
| Income Before Tax | -6.80M | -9.74M | -13.07M | -9.29M | -8.30M | -6.70M | -2.20M | -3.37M | -1.47M | -5.98M | -428.05K | 1.42M | -10.82M | -10.45M | -6.07M | 0.00 |
| Income Before Tax Ratio | -234.42% | -332.23% | -543.73% | -580.18% | -493.59% | -517.03% | -290.41% | -568.52% | -464.06% | -47.75% | -2.50% | 9.09% | -70.33% | -65.80% | -36.26% | 0.00% |
| Income Tax Expense | 0.00 | -364.37K | -148.60K | 31.32K | 10.31K | -1.01M | -66.69K | 238.07K | -69.44M | 127.39K | 229.83K | 68.00K | 63.11K | 64.23K | 9.71K | 190.78K |
| Net Income | -6.80M | -9.37M | -12.92M | -9.33M | -8.31M | -5.69M | -2.14M | -3.61M | 65.79M | -5.98M | -428.05K | 1.35M | -10.88M | -10.51M | -6.08M | -190.78K |
| Net Income Ratio | -234.42% | -319.79% | -537.54% | -582.13% | -494.21% | -439.36% | -281.61% | -608.67% | 20,837.76% | -47.75% | -2.50% | 8.65% | -70.74% | -66.20% | -36.32% | -90.30% |
| EPS | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.42 | -0.04 |
| EPS Diluted | -0.24 | -0.33 | -0.46 | -0.34 | -0.31 | -0.21 | -0.07 | -0.10 | 1.91 | -0.18 | -0.01 | 0.04 | -0.45 | -0.48 | -0.37 | -0.04 |
| Weighted Avg Shares Out | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 33.74M | 24.42M | 22.13M | 14.39M | 5.00M |
| Weighted Avg Shares Out (Dil) | 28.80M | 28.36M | 27.84M | 27.47M | 27.00M | 27.67M | 28.92M | 36.54M | 34.37M | 34.10M | 32.80M | 34.23M | 24.42M | 22.13M | 16.32M | 5.00M |
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic Attends Investor Events in December
JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical Study Report available in the coming weeks JUPITER, Fla., Nov. 29, 2023 (GLOBE NEWSWIRE)...
Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa
JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein...
Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript
Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants...
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
JUPITER, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Dyadic to Present at Industry Events in November
JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs...
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Dyadic Appoints Doug Pace to Its Executive Leadership Team
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and...
Source: https://incomestatements.info
Category: Stock Reports